Active Biotech AB, a listed Swedish drug development company focused on manipulating the immune system to treat major diseases, said its net loss for the first half of 2010 narrowed to SEK 108.1 million from SEK 118.6 million a year earlier.
Active Biotech AB, a listed Swedish drug development company focused on manipulating the immune system to treat major diseases, said its net loss for the first half of 2010 narrowed to SEK 108.1 million from SEK 118.6 million a year earlier.